Powered by

Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update

Mar 02, 2017 - GlobeNewswire

Advanced timing for top-line data readout of Phase 3 study of omadacycline in community-acquired bacterial pneumonia (CABP)Conference call scheduled for 8:30 a.m. EST on March 2, 2017

BOSTON, March 02, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the full year and quarter ended December 31, 20...